$AMRX
Amneal Pharmaceuticals, Inc. Stock $amrx

$amrx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000172312822000006 Filed on March 01, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$536.9M	$2.094B	$510.0M
YoY Change	5.27%	5.08%	28.36%
Cost Of Revenue	$348.5M	$1.302B	$343.0M
YoY Change	1.6%	-2.07%	25.46%
Gross Profit	$188.4M	$769.0M	$167.1M
YoY Change	12.75%	22.37%	51.59%
Gross Profit Margin	35.09%	36.73%	32.76%
Selling, General & Admin	$98.37M	$365.5M	$88.40M
YoY Change	11.27%	11.87%	11.76%
% of Gross Profit	52.21%	47.53%	52.9%
Research & Development	$51.87M	$201.8M	$53.50M
YoY Change	-3.04%	12.18%	11.23%
% of Gross Profit	27.53%	26.25%	32.02%
Depreciation & Amortization	$61.18M	$60.71M	$59.90M
YoY Change	2.14%	0.47%	10.31%
% of Gross Profit	32.47%	7.89%	35.85%
Operating Expenses	$150.1M	$567.4M	$141.9M
YoY Change	5.81%	11.98%	11.64%
Operating Profit	$38.27M	$152.7M	$25.20M
YoY Change	51.85%	67.53%	-249.41%
Interest Expense	-$34.13M	-$136.3M	-$26.10M
YoY Change	30.75%	-6.63%	-23.46%
% of Operating Profit	-89.18%	-89.27%	-103.57%
Other Income/Expense, Net	$6.633M	-$121.4M	$500.0K
YoY Change	1226.6%	-4.4%	-350.0%
Pretax Income	-$16.32M	$31.37M	-$5.500M
YoY Change	196.71%	-187.66%	-90.37%
Income Tax	$4.140M	$11.20M	$1.500M
% Of Pretax Income		35.69%
Net Earnings	-$6.377M	$13.16M	-$3.000M
YoY Change	112.57%	-80.58%	-95.38%
Net Earnings / Revenue	-1.19%	0.63%	-0.59%
Basic Earnings Per Share		$0.07
Diluted Earnings Per Share	-$42.69K	$0.07	-$20.33K
COMMON SHARES
Basic Shares Outstanding		148.9M shares
Diluted Shares Outstanding		151.8M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$247.8M	$247.8M	$341.4M
YoY Change	-27.42%	-27.42%	125.79%
Cash & Equivalents	$247.8M	$247.8M	$341.4M
Short-Term Investments
Other Short-Term Assets	$55.19M	$55.19M	$45.30M
YoY Change	21.83%	21.83%	-36.91%
Inventory	$489.4M	$489.4M	$490.6M
Prepaid Expenses
Receivables	$662.6M	$662.6M	$638.9M
Other Receivables	$9.770M	$65.16M	$17.12M
Total Short-Term Assets	$1.520B	$1.520B	$1.552B
YoY Change	-2.03%	-2.02%	28.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$514.2M	$639.0M	$477.8M
YoY Change	7.62%	5.59%	-0.05%
Goodwill	$593.0M		$522.8M
YoY Change	13.43%		24.63%
Intangibles	$1.167B		$1.305B
YoY Change	-10.56%		-5.65%
Long-Term Investments
YoY Change
Other Assets	$20.61M	$20.61M	$22.34M
YoY Change	-7.74%	-5.87%	-49.53%
Total Long-Term Assets	$2.420B	$2.420B	$2.454B
YoY Change	-1.42%	-1.42%	-0.05%
TOTAL ASSETS
Total Short-Term Assets	$1.520B	$1.520B	$1.552B
Total Long-Term Assets	$2.420B	$2.420B	$2.454B
Total Assets	$3.940B	$3.940B	$4.006B
YoY Change	-1.66%	-1.66%	9.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$131.1M	$131.1M	$153.1M
YoY Change	-14.4%	-14.38%	48.65%
Accrued Expenses	$12.32M	$404.1M	$9.300M
YoY Change	32.49%	-12.97%	-35.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$30.61M	$33.72M	$44.23M
YoY Change	-30.78%	-30.34%	105.91%
Total Short-Term Liabilities	$677.2M	$677.2M	$676.9M
YoY Change	0.05%	0.05%	22.98%
LONG-TERM LIABILITIES
Long-Term Debt	$2.680B	$2.778B	$2.735B
YoY Change	-2.02%	-1.97%	4.84%
Other Long-Term Liabilities	$38.90M	$100.2M	$83.37M
YoY Change	-53.33%	-27.5%	110.61%
Total Long-Term Liabilities	$2.879B	$2.879B	$2.972B
YoY Change	-3.16%	-3.16%	7.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$677.2M	$677.2M	$676.9M
Total Long-Term Liabilities	$2.879B	$2.879B	$2.972B
Total Liabilities	$3.556B	$3.579B	$3.649B
YoY Change	-2.56%	-3.33%	9.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$276.2M		-$286.8M
YoY Change	-3.7%		-24.1%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$360.3M	$360.3M	$303.3M
YoY Change
Total Liabilities & Shareholders Equity	$3.940B	$3.940B	$4.006B
YoY Change	-1.66%	-1.66%	9.28%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$6.377M	$13.16M	-$3.000M
YoY Change	112.57%	-80.58%	-95.38%
Depreciation, Depletion And Amortization	$61.18M	$60.71M	$59.90M
YoY Change	2.14%	0.47%	10.31%
Cash From Operating Activities	$63.26M	$241.8M	$106.0M
YoY Change	-40.32%	-36.2%	-308.25%
INVESTING ACTIVITIES
Capital Expenditures	-$19.25M	$47.73M	-$31.80M
YoY Change	-39.45%	-15.44%	576.6%
Acquisitions		$146.5M
YoY Change		-41.7%
Other Investing Activities	-$67.72M	-$141.5M	$0.00
YoY Change		-43.7%
Cash From Investing Activities	-$86.97M	-$194.2M	-$31.70M
YoY Change	174.35%	-38.85%	560.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-30.35M	-$138.1M	-11.30M
YoY Change	168.58%	-204.79%	54.79%
NET CHANGE
Cash From Operating Activities	63.26M	$241.8M	106.0M
Cash From Investing Activities	-86.97M	-$194.2M	-31.70M
Cash From Financing Activities	-30.35M	-$138.1M	-11.30M
Net Change In Cash	-54.06M	-$90.38M	63.00M
YoY Change	-185.81%	-146.52%	-200.0%
FREE CASH FLOW
Cash From Operating Activities	$63.26M	$241.8M	$106.0M
Capital Expenditures	-$19.25M	$47.73M	-$31.80M
Free Cash Flow	$82.52M	$194.1M	$137.8M
YoY Change	-40.12%	-39.83%	-398.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001723128
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2018	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38485
CY2021	dei	Entity Registrant Name EntityRegistrantName	Amneal Pharmaceuticals, Inc.
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Crossing Boulevard
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	32-0546926
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
CY2021	dei	City Area Code CityAreaCode	908
CY2021	dei	Local Phone Number LocalPhoneNumber	947-3120
CY2021	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $0.01 per share
CY2021	dei	Trading Symbol TradingSymbol	AMRX
CY2021	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	750794557	USD
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Iselin, NJ
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2093669000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1992523000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1626373000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1302004000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1329551000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1147214000	USD
CY2021	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	22692000	USD
CY2020	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	34579000	USD
CY2019	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	126162000	USD
CY2021	us-gaap	Gross Profit GrossProfit	768973000	USD
CY2020	us-gaap	Gross Profit GrossProfit	628393000	USD
CY2019	us-gaap	Gross Profit GrossProfit	352997000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	365504000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	326727000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	289598000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	201847000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	179930000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	188049000	USD
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	710000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2680000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	46619000	USD
CY2021	us-gaap	Royalty Expense RoyaltyExpense	7716000	USD
CY2020	us-gaap	Royalty Expense RoyaltyExpense	10655000	USD
CY2019	us-gaap	Royalty Expense RoyaltyExpense	14238000	USD
CY2021	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	8055000	USD
CY2020	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	8988000	USD
CY2019	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	16388000	USD
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-25000000	USD
CY2020	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-5860000	USD
CY2019	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-12442000	USD
CY2021	us-gaap	Restructuring Charges RestructuringCharges	1857000	USD
CY2020	us-gaap	Restructuring Charges RestructuringCharges	2398000	USD
CY2019	us-gaap	Restructuring Charges RestructuringCharges	34345000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	200000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2021	us-gaap	Unusual Or Infrequent Item Net Gain Loss UnusualOrInfrequentItemNetGainLoss	5368000	USD
CY2020	us-gaap	Unusual Or Infrequent Item Net Gain Loss UnusualOrInfrequentItemNetGainLoss	0	USD
CY2019	us-gaap	Unusual Or Infrequent Item Net Gain Loss UnusualOrInfrequentItemNetGainLoss	0	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	152716000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	91155000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-248682000	USD
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-136325000	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-145998000	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-168205000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-355000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	16350000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4962000	USD
CY2021	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	USD
CY2020	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	123000	USD
CY2019	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	7258000	USD
CY2021	amrx	Gain From Reduction Of Tax Receivable Agreement Liability GainFromReductionOfTaxReceivableAgreementLiability	0	USD
CY2020	amrx	Gain From Reduction Of Tax Receivable Agreement Liability GainFromReductionOfTaxReceivableAgreementLiability	0	USD
CY2019	amrx	Gain From Reduction Of Tax Receivable Agreement Liability GainFromReductionOfTaxReceivableAgreementLiability	192884000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15330000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2590000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1465000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-121350000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-126935000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28440000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	31366000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35780000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-220242000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11196000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-104358000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	383331000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	20170000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	68578000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-603573000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9546000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-22481000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-241656000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10624000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	91059000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-361917000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.62
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.74
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.61
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.74
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148922000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147443000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132106000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151821000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148913000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132106000	shares
CY2021	us-gaap	Profit Loss ProfitLoss	20170000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	68578000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-603573000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9546000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-22481000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-241656000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10624000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	91059000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-361917000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-8618000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-13500000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1233000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-3413000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8618000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-13500000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2180000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	42430000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-70276000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	16373000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	17095000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-42573000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	10058000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16717000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-41203000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	8495000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	27341000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	49856000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-353422000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	247790000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	341378000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	8949000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	5743000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	662583000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	638895000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	489389000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	490649000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	110218000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	73467000	USD
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1179000	USD
CY2020Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1407000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1520108000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1551539000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	514158000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	477754000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	593017000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	522814000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1166922000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1304626000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20614000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22344000	USD
CY2021Q4	us-gaap	Assets Assets	3939664000	USD
CY2020Q4	us-gaap	Assets Assets	4006033000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	583345000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	611867000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	30614000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	44228000	USD
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	47861000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	7561000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	677243000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	676902000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2680053000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2735264000	USD
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	38038000	USD
CY2020Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	36440000	USD
CY2021Q4	us-gaap	Due To Affiliate Noncurrent DueToAffiliateNoncurrent	9619000	USD
CY2020Q4	us-gaap	Due To Affiliate Noncurrent DueToAffiliateNoncurrent	1584000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38903000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	83365000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2878541000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2972395000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	16907000	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	11804000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	658350000	USD
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	628413000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-276197000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-286821000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24827000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-41318000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	360340000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	303271000	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	6633000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	41661000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	366973000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	344932000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3939664000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4006033000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	344932000	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	11804000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	13163000	USD
CY2021	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	7007000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-8618000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28412000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	853000	USD
CY2021	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-2713000	USD
CY2021	amrx	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders Tax Distribution NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersTaxDistribution	53486000	USD
CY2021	amrx	Temporary Equity Tax Distribution TemporaryEquityTaxDistribution	3646000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	42430000	USD
CY2021	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	2000000	USD
CY2021	amrx	Temporary Equity Increase From Business Combination TemporaryEquityIncreaseFromBusinessCombination	1742000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	366973000	USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	16907000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	346788000	USD
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	67791000	USD
CY2020	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	787000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-13500000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20750000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	321000	USD
CY2020	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-863000	USD
CY2020	amrx	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders Tax Distribution NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersTaxDistribution	2779000	USD
CY2020	amrx	Temporary Equity Tax Distribution TemporaryEquityTaxDistribution	458000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-70276000	USD
CY2020	amrx	Noncontrolling Interest Decrease Redemptions Or Purchase Of Interests Decrease From Earnings Distributions NoncontrollingInterestDecreaseRedemptionsOrPurchaseOfInterestsDecreaseFromEarningsDistributions	-3300000	USD
CY2020	amrx	Temporary Equity Increase From Business Combination TemporaryEquityIncreaseFromBusinessCombination	11475000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	344932000	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	11804000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	896363000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-603573000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1233000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21679000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1400000	USD
CY2019	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-1113000	USD
CY2019	amrx	Stock Repurchased And Reissued During Period Value StockRepurchasedAndReissuedDuringPeriodValue	0	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2019	amrx	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders Tax Distribution NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersTaxDistribution	82000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	16373000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	-3413000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	346788000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	20170000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	68578000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-603573000	USD
CY2021	amrx	Gain Loss From Reduction Of Tax Receivable Agreement Liability GainLossFromReductionOfTaxReceivableAgreementLiability	0	USD
CY2020	amrx	Gain Loss From Reduction Of Tax Receivable Agreement Liability GainLossFromReductionOfTaxReceivableAgreementLiability	0	USD
CY2019	amrx	Gain Loss From Reduction Of Tax Receivable Agreement Liability GainLossFromReductionOfTaxReceivableAgreementLiability	192884000	USD
CY2021	amrx	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	233406000	USD
CY2020	amrx	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	235387000	USD
CY2019	amrx	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	207235000	USD
CY2021	amrx	Amortization Transition Agreement Payment AmortizationTransitionAgreementPayment	0	USD
CY2020	amrx	Amortization Transition Agreement Payment AmortizationTransitionAgreementPayment	0	USD
CY2019	amrx	Amortization Transition Agreement Payment AmortizationTransitionAgreementPayment	36393000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-175000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	16728000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-7342000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	9203000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	8678000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	6478000	USD
CY2021	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	USD
CY2020	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	123000	USD
CY2019	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	7258000	USD
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	23402000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	37259000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	172781000	USD
CY2021	amrx	Noncash Restructuring Costs And Asset Impairment Charges NoncashRestructuringCostsAndAssetImpairmentCharges	0	USD
CY2020	amrx	Noncash Restructuring Costs And Asset Impairment Charges NoncashRestructuringCostsAndAssetImpairmentCharges	-536000	USD
CY2019	amrx	Noncash Restructuring Costs And Asset Impairment Charges NoncashRestructuringCostsAndAssetImpairmentCharges	12459000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	371716000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	200000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	28412000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	20750000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	21679000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	54660000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	75236000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	82245000	USD
CY2021	amrx	Insurance Recoveries For Property And Equipment Losses InsuranceRecoveriesForPropertyAndEquipmentLosses	5000000	USD
CY2020	amrx	Insurance Recoveries For Property And Equipment Losses InsuranceRecoveriesForPropertyAndEquipmentLosses	0	USD
CY2019	amrx	Insurance Recoveries For Property And Equipment Losses InsuranceRecoveriesForPropertyAndEquipmentLosses	0	USD
CY2021	amrx	Noncash Property Losses NoncashPropertyLosses	5152000	USD
CY2020	amrx	Noncash Property Losses NoncashPropertyLosses	0	USD
CY2019	amrx	Noncash Property Losses NoncashPropertyLosses	0	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5633000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-11818000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7309000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23621000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16787000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	132726000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	49015000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	113782000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	20393000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	21981000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-33312000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-38870000	USD
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-7311000	USD
CY2020	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-412000	USD
CY2019	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	939000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-43932000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	307000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10257000	USD
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-2355000	USD
CY2020	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	1646000	USD
CY2019	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	5228000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	241820000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	379001000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1705000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47728000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56445000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47181000	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1700000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4350000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	50250000	USD
CY2021	amrx	Payments To Acquire Property Plant And Equipment Deposits PaymentsToAcquirePropertyPlantAndEquipmentDeposits	3211000	USD
CY2020	amrx	Payments To Acquire Property Plant And Equipment Deposits PaymentsToAcquirePropertyPlantAndEquipmentDeposits	5391000	USD
CY2019	amrx	Payments To Acquire Property Plant And Equipment Deposits PaymentsToAcquirePropertyPlantAndEquipmentDeposits	0	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	146543000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	251360000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	5000000	USD
CY2020	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	0	USD
CY2019	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	43017000	USD
CY2021	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	USD
CY2019	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	34834000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-194182000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-317546000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19580000	USD
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4102000	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	180000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	0	USD
CY2021	amrx	Repayments Of Long Term Debt And Financing Lease Obligations RepaymentsOfLongTermDebtAndFinancingLeaseObligations	-78086000	USD
CY2020	amrx	Repayments Of Long Term Debt And Financing Lease Obligations RepaymentsOfLongTermDebtAndFinancingLeaseObligations	-35933000	USD
CY2019	amrx	Repayments Of Long Term Debt And Financing Lease Obligations RepaymentsOfLongTermDebtAndFinancingLeaseObligations	-27000000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	853000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	321000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1400000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2664000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	863000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	926000	USD
CY2021	amrx	Payments For Acquisition Of Non Controlling Interests PaymentsForAcquisitionOfNonControllingInterests	0	USD
CY2020	amrx	Payments For Acquisition Of Non Controlling Interests PaymentsForAcquisitionOfNonControllingInterests	3300000	USD
CY2019	amrx	Payments For Acquisition Of Non Controlling Interests PaymentsForAcquisitionOfNonControllingInterests	3543000	USD
CY2021	amrx	Tax Distribution To Noncontrolling Interest Financing Activities TaxDistributionToNoncontrollingInterestFinancingActivities	57132000	USD
CY2020	amrx	Tax Distribution To Noncontrolling Interest Financing Activities TaxDistributionToNoncontrollingInterestFinancingActivities	3237000	USD
CY2019	amrx	Tax Distribution To Noncontrolling Interest Financing Activities TaxDistributionToNoncontrollingInterestFinancingActivities	13494000	USD
CY2021	amrx	Finance Lease Principal Payments Related Party FinanceLeasePrincipalPaymentsRelatedParty	93000	USD
CY2020	amrx	Finance Lease Principal Payments Related Party FinanceLeasePrincipalPaymentsRelatedParty	1079000	USD
CY2019	amrx	Finance Lease Principal Payments Related Party FinanceLeasePrincipalPaymentsRelatedParty	2270000	USD
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1000000	USD
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2019	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-138122000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	131807000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-45833000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1037000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2249000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-90382000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	194299000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-65957000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	347121000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152822000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218779000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	256739000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	347121000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152822000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	247790000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	341378000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151197000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	8949000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	5743000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1625000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	256739000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	347121000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152822000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	121747000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	130186000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	158568000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-15558000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	100141000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10255000	USD
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	14162000	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	36033000	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
CY2021	amrx	Noncash Or Part Noncash Acquisition Deferred Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionDeferredConsiderationForAcquisitionRelatedParty	30099000	USD
CY2020	amrx	Noncash Or Part Noncash Acquisition Deferred Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionDeferredConsiderationForAcquisitionRelatedParty	0	USD
CY2019	amrx	Noncash Or Part Noncash Acquisition Deferred Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionDeferredConsiderationForAcquisitionRelatedParty	0	USD
CY2021	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisitionRelatedParty	5700000	USD
CY2020	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisitionRelatedParty	0	USD
CY2019	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisitionRelatedParty	0	USD
CY2021	amrx	Intangible Asset Expenditures Incurred But Not Yet Paid IntangibleAssetExpendituresIncurredButNotYetPaid	300000	USD
CY2020	amrx	Intangible Asset Expenditures Incurred But Not Yet Paid IntangibleAssetExpendituresIncurredButNotYetPaid	0	USD
CY2019	amrx	Intangible Asset Expenditures Incurred But Not Yet Paid IntangibleAssetExpendituresIncurredButNotYetPaid	0	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.</span></div>
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9000000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6000000	USD
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period balances related to (i) financing lease right-of-use assets of $10 million formerly included in other assets, (ii) current portion of financing lease liabilities of $2 million formerly included in accounts payable and accrued expenses, and (iii) long-term lease liabilities of $2 million formerly included in other long-term liabilities as of December 31, 2020 have been reclassified to their respective balance sheet captions to conform to the current period presentation in the consolidated balance sheets.</span></div>
CY2021Q4	amrx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets Including Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill	91013000	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	2229000	USD
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2093861000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2023609000	USD
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	22523000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	54083000	USD
CY2021	amrx	Business Acquisition Pro Forma Net Income Loss Attributable To Common Shareholders BusinessAcquisitionProFormaNetIncomeLossAttributableToCommonShareholders	11802000	USD
CY2020	amrx	Business Acquisition Pro Forma Net Income Loss Attributable To Common Shareholders BusinessAcquisitionProFormaNetIncomeLossAttributableToCommonShareholders	80643000	USD
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	8000000	USD
CY2020	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	9000000	USD
CY2019	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	16000000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2093669000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1992523000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1626373000	USD
CY2021	us-gaap	Restructuring Charges RestructuringCharges	1857000	USD
CY2020	us-gaap	Restructuring Charges RestructuringCharges	2398000	USD
CY2019	us-gaap	Restructuring Charges RestructuringCharges	34345000	USD
CY2021Q4	amrx	Number Of Companies NumberOfCompanies	55	company
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	10000000000	INR
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	134000000	USD
CY2021Q4	amrx	Government Grant Eligible Term GovernmentGrantEligibleTerm	P6Y
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	417000000	USD
CY2021	amrx	Percentage Of Tax Benefits Under Tax Receivable Agreement PercentageOfTaxBenefitsUnderTaxReceivableAgreement	0.85
CY2019Q4	amrx	Reversal Of Accrued Tax Receivable Agreement Liability ReversalOfAccruedTaxReceivableAgreementLiability	193000000	USD
CY2020	amrx	Percentage Of Tax Benefits Under Tax Receivable Agreement PercentageOfTaxBenefitsUnderTaxReceivableAgreement	0.85
CY2020Q4	amrx	Liabilities Under Tax Receivable Agreement Noncurrent LiabilitiesUnderTaxReceivableAgreementNoncurrent	206000000	USD
CY2020Q4	amrx	Liabilities Under Tax Receivable Agreement Noncurrent LiabilitiesUnderTaxReceivableAgreementNoncurrent	206000000	USD
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	345000000	USD
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-110000000	USD
CY2020Q3	amrx	Income Taxes Receivable Net Operating Loss Cares Act Amount Refunded IncomeTaxesReceivableNetOperatingLossCARESActAmountRefunded	106000000	USD
CY2020Q3	amrx	Income Taxes Receivable Net Operating Loss Cares Act IncomeTaxesReceivableNetOperatingLossCARESAct	110000000	USD
CY2020Q3	amrx	Income Taxes Receivable Net Operating Loss Cares Act Interest IncomeTaxesReceivableNetOperatingLossCARESActInterest	4000000	USD
CY2021Q1	amrx	Income Taxes Receivable Net Operating Loss Cares Act Amount Refunded IncomeTaxesReceivableNetOperatingLossCARESActAmountRefunded	2000000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000000	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.357
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-104000000	USD
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	2.917
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	383000000	USD
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-1.74
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	-110000000	USD
CY2021	amrx	Income Tax Returns Examination Period IncomeTaxReturnsExaminationPeriod	P3Y
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	31366000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35780000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-220242000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1311000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-113754000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-2760000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	9885000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	9396000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	14375000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	11196000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-104358000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	11615000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	365546000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	6170000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	371716000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11196000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-104358000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	383331000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	0.042
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.020
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.151
CY2021	amrx	Effective Income Tax Rate Reconciliation Loss No Benefit Recognized Percent EffectiveIncomeTaxRateReconciliationLossNoBenefitRecognizedPercent	0.064
CY2020	amrx	Effective Income Tax Rate Reconciliation Loss No Benefit Recognized Percent EffectiveIncomeTaxRateReconciliationLossNoBenefitRecognizedPercent	-0.298
CY2019	amrx	Effective Income Tax Rate Reconciliation Loss No Benefit Recognized Percent EffectiveIncomeTaxRateReconciliationLossNoBenefitRecognizedPercent	-0.258
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.173
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.071
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.055
CY2021	amrx	Effective Income Tax Rate Reconciliation Permanent Book Tax Differences Percent EffectiveIncomeTaxRateReconciliationPermanentBookTaxDifferencesPercent	0.048
CY2020	amrx	Effective Income Tax Rate Reconciliation Permanent Book Tax Differences Percent EffectiveIncomeTaxRateReconciliationPermanentBookTaxDifferencesPercent	0
CY2019	amrx	Effective Income Tax Rate Reconciliation Permanent Book Tax Differences Percent EffectiveIncomeTaxRateReconciliationPermanentBookTaxDifferencesPercent	0
CY2021	amrx	Effective Income Tax Rate Reconciliation Tax Receivable Agreement Revaluation EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementRevaluation	0
CY2020	amrx	Effective Income Tax Rate Reconciliation Tax Receivable Agreement Revaluation EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementRevaluation	0
CY2019	amrx	Effective Income Tax Rate Reconciliation Tax Receivable Agreement Revaluation EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementRevaluation	0.184
CY2021	amrx	Effective Income Tax Rate Reconciliation Cares Act Percent EffectiveIncomeTaxRateReconciliationCARESActPercent	0
CY2020	amrx	Effective Income Tax Rate Reconciliation Cares Act Percent EffectiveIncomeTaxRateReconciliationCARESActPercent	1.399
CY2019	amrx	Effective Income Tax Rate Reconciliation Cares Act Percent EffectiveIncomeTaxRateReconciliationCARESActPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.135
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1.632
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1.682
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.045
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.065
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.012
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.357
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	2.917
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-1.740
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	422812000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	470193000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41235000	USD
CY2021	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Current Year Net Operating Losses And Temporary Differences ValuationAllowanceDeferredTaxAssetIncreaseDecreaseCurrentYearNetOperatingLossesAndTemporaryDifferences	-10828000	USD
CY2020	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Current Year Net Operating Losses And Temporary Differences ValuationAllowanceDeferredTaxAssetIncreaseDecreaseCurrentYearNetOperatingLossesAndTemporaryDifferences	-54971000	USD
CY2019	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Current Year Net Operating Losses And Temporary Differences ValuationAllowanceDeferredTaxAssetIncreaseDecreaseCurrentYearNetOperatingLossesAndTemporaryDifferences	424692000	USD
CY2021	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Share Based Compensation ValuationAllowanceDeferredTaxAssetIncreaseDecreaseShareBasedCompensation	5513000	USD
CY2020	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Share Based Compensation ValuationAllowanceDeferredTaxAssetIncreaseDecreaseShareBasedCompensation	0	USD
CY2019	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Share Based Compensation ValuationAllowanceDeferredTaxAssetIncreaseDecreaseShareBasedCompensation	0	USD
CY2021	amrx	Valuation Allowance Increase Decrease Recorded Against Additional Paid In Capital ValuationAllowanceIncreaseDecreaseRecordedAgainstAdditionalPaidInCapital	2842000	USD
CY2020	amrx	Valuation Allowance Increase Decrease Recorded Against Additional Paid In Capital ValuationAllowanceIncreaseDecreaseRecordedAgainstAdditionalPaidInCapital	-1631000	USD
CY2019	amrx	Valuation Allowance Increase Decrease Recorded Against Additional Paid In Capital ValuationAllowanceIncreaseDecreaseRecordedAgainstAdditionalPaidInCapital	4266000	USD
CY2021	amrx	Valuation Allowance Increase Decrease Recorded Against Other Comprehensive Income ValuationAllowanceIncreaseDecreaseRecordedAgainstOtherComprehensiveIncome	-3751000	USD
CY2020	amrx	Valuation Allowance Increase Decrease Recorded Against Other Comprehensive Income ValuationAllowanceIncreaseDecreaseRecordedAgainstOtherComprehensiveIncome	9221000	USD
CY2019	amrx	Valuation Allowance Increase Decrease Recorded Against Other Comprehensive Income ValuationAllowanceIncreaseDecreaseRecordedAgainstOtherComprehensiveIncome	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	498000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	410000	USD
CY2020Q4	amrx	Deferred Tax Assets Partnership Interest DeferredTaxAssetsPartnershipInterest	212402000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	416588000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	422812000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	470193000	USD
CY2021Q4	amrx	Deferred Tax Assets Partnership Interest DeferredTaxAssetsPartnershipInterest	200872000	USD
CY2021Q4	amrx	Deferred Tax Assets Projected Imputed Interest On Tax Receivable Agreement DeferredTaxAssetsProjectedImputedInterestOnTaxReceivableAgreement	25615000	USD
CY2020Q4	amrx	Deferred Tax Assets Projected Imputed Interest On Tax Receivable Agreement DeferredTaxAssetsProjectedImputedInterestOnTaxReceivableAgreement	25539000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	73861000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77255000	USD
CY2021Q4	amrx	Deferred Tax Assets Tax Credit Carryforwards Interest DeferredTaxAssetsTaxCreditCarryforwardsInterest	46407000	USD
CY2020Q4	amrx	Deferred Tax Assets Tax Credit Carryforwards Interest DeferredTaxAssetsTaxCreditCarryforwardsInterest	45425000	USD
CY2021Q4	amrx	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	1300000	USD
CY2020Q4	amrx	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	1502000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5513000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	28380000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	28400000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	34142000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	31879000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	416588000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	422812000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	416588000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	422812000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5000000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6000000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	5000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	5000000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	6000000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	100000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	-300000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	400000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	800000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	800000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	1000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5368000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6176000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7206000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	131000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	125000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	83000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	10000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	443000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	732000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	1376000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	381000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5489000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5368000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6176000	USD
CY2021Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	93000000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10624000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	91059000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-361917000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148922000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147443000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132106000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151821000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148913000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132106000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.62
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.74
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.61
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.74
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1191792000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1291785000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1665000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1396000	USD
CY2021Q4	amrx	Contract Charge Backs And Sales Volume Allowances Current ContractChargeBacksAndSalesVolumeAllowancesCurrent	503902000	USD
CY2020Q4	amrx	Contract Charge Backs And Sales Volume Allowances Current ContractChargeBacksAndSalesVolumeAllowancesCurrent	628804000	USD
CY2021Q4	amrx	Cash Discount Allowances Current CashDiscountAllowancesCurrent	23642000	USD
CY2020Q4	amrx	Cash Discount Allowances Current CashDiscountAllowancesCurrent	22690000	USD
CY2021Q4	amrx	Allowance For Accounts Receivable Current AllowanceForAccountsReceivableCurrent	529209000	USD
CY2020Q4	amrx	Allowance For Accounts Receivable Current AllowanceForAccountsReceivableCurrent	652890000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	662583000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	638895000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	214508000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	209180000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	47802000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	40937000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	227079000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	240532000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	489389000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	490649000	USD
CY2021	amrx	Operating And Finance Lease Expense OperatingAndFinanceLeaseExpense	20000000	USD
CY2020	amrx	Operating And Finance Lease Expense OperatingAndFinanceLeaseExpense	26000000	USD
CY2019	amrx	Operating And Finance Lease Expense OperatingAndFinanceLeaseExpense	26000000	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1000000	USD
CY2019	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2000000	USD
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2021	amrx	Operating Short Term And Variable Lease Cost OperatingShortTermAndVariableLeaseCost	15057000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	3468000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4601000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4773000	USD
CY2020	amrx	Operating Short Term And Variable Lease Cost OperatingShortTermAndVariableLeaseCost	21664000	USD
CY2019	amrx	Operating Short Term And Variable Lease Cost OperatingShortTermAndVariableLeaseCost	22544000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4713000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4487000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4641000	USD
CY2021	amrx	Finance Lease Cost FinanceLeaseCost	9314000	USD
CY2020	amrx	Finance Lease Cost FinanceLeaseCost	9260000	USD
CY2019	amrx	Finance Lease Cost FinanceLeaseCost	8109000	USD
CY2021	us-gaap	Lease Cost LeaseCost	24371000	USD
CY2020	us-gaap	Lease Cost LeaseCost	30924000	USD
CY2019	us-gaap	Lease Cost LeaseCost	30653000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	60370000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	5572000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11363000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	5474000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58739000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	63999000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62525000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	64475000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	68217000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	63352000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	65463000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4601000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4773000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	15006000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	18780000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3179000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2768000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12006000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3305000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P21Y
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P21Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.069
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.071
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.071
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.071
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	16136000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	7492000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	16412000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	6726000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	15215000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7400000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	5474000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9712000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	89862000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	76238000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	120600000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12239000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	57248000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	63999000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	63352000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13473000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	7428000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13402000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	6992000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13446000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	6381000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12246000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	5488000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8961000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	5474000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	16822000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	95336000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	78350000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	127099000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15825000	USD
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	61636000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62525000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	65463000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1174000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1696000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	7962000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	6916000	USD
CY2021Q4	amrx	Prepaid Regulatory Fees Current PrepaidRegulatoryFeesCurrent	3710000	USD
CY2020Q4	amrx	Prepaid Regulatory Fees Current PrepaidRegulatoryFeesCurrent	3565000	USD
CY2021Q4	amrx	Income And Other Taxes Receivable IncomeAndOtherTaxesReceivable	8850000	USD
CY2020Q4	amrx	Income And Other Taxes Receivable IncomeAndOtherTaxesReceivable	11882000	USD
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	16085000	USD
CY2020Q4	us-gaap	Prepaid Taxes PrepaidTaxes	5542000	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	42770000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	17117000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	17309000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	21836000	USD
CY2021Q4	amrx	Chargebacks Receivable Current ChargebacksReceivableCurrent	12358000	USD
CY2020Q4	amrx	Chargebacks Receivable Current ChargebacksReceivableCurrent	4913000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	110218000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	73467000	USD
CY2021	us-gaap	Depreciation Depreciation	60705000	USD
CY2021Q4	us-gaap	Loss Contingency Receivable LossContingencyReceivable	33000000	USD
CY2020Q4	us-gaap	Loss Contingency Receivable LossContingencyReceivable	6000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	908720000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	809893000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	394562000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	332139000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	514158000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	477754000	USD
CY2020	us-gaap	Depreciation Depreciation	60420000	USD
CY2019	us-gaap	Depreciation Depreciation	63283000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	522814000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	522814000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1256412000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	419504000	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	70584000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	103679000	USD
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-381000	USD
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-369000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	593017000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	494915000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	761497000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1286896000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	361665000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	925231000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	405425000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	405425000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	379395000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	379395000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1661837000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	494915000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1166922000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1666291000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	361665000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1304626000	USD
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	17700000	USD
CY2020	amrx	Finite Lived Intangible Assets Number Of Products Impaired FiniteLivedIntangibleAssetsNumberOfProductsImpaired	6	product
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172701000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	174967000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	143952000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	405000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	158907000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	146196000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	136300000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	97526000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	53192000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	169376000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	761497000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	131084000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	153140000	USD
CY2021Q4	amrx	Accrued Sales Returns Allowance Current AccruedSalesReturnsAllowanceCurrent	161978000	USD
CY2020Q4	amrx	Accrued Sales Returns Allowance Current AccruedSalesReturnsAllowanceCurrent	174984000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	62098000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	58922000	USD
CY2021Q4	amrx	Accrued Sales Rebates Current AccruedSalesRebatesCurrent	85737000	USD
CY2020Q4	amrx	Accrued Sales Rebates Current AccruedSalesRebatesCurrent	131088000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	20893000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	21777000	USD
CY2021Q4	amrx	Rebates And Chargebacks RebatesAndChargebacks	10226000	USD
CY2020Q4	amrx	Rebates And Chargebacks RebatesAndChargebacks	10226000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9926000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10748000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2523000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	5538000	USD
CY2021Q4	amrx	Liabilities For Legal Proceedings And Claims LiabilitiesForLegalProceedingsAndClaims	58000000	USD
CY2020Q4	amrx	Liabilities For Legal Proceedings And Claims LiabilitiesForLegalProceedingsAndClaims	11000000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	40880000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	34444000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2805750000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	20083000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	26258000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	583345000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	611867000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2730750000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	2710667000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	2779492000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	30614000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	44228000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2680053000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2735264000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38903000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	83365000	USD
CY2021Q4	us-gaap	Interest Rate Cash Flow Hedge Liability At Fair Value InterestRateCashFlowHedgeLiabilityAtFairValue	11473000	USD
CY2021Q4	amrx	Deferred Compensation Plan Liabilities Fair Value Disclosures DeferredCompensationPlanLiabilitiesFairValueDisclosures	13883000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5900000	USD
CY2020Q4	us-gaap	Interest Rate Cash Flow Hedge Liability At Fair Value InterestRateCashFlowHedgeLiabilityAtFairValue	53903000	USD
CY2020Q4	amrx	Deferred Compensation Plan Liabilities Fair Value Disclosures DeferredCompensationPlanLiabilitiesFairValueDisclosures	14007000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6000000	USD
CY2021Q4	us-gaap	Aoci Loss Cash Flow Hedge Cumulative Gain Loss After Tax AociLossCashFlowHedgeCumulativeGainLossAfterTax	-11500000	USD
CY2021Q4	us-gaap	Loss Contingency Receivable LossContingencyReceivable	33000000	USD
CY2020Q4	us-gaap	Loss Contingency Receivable LossContingencyReceivable	6000000	USD
CY2021Q4	amrx	Loss Contingency Pending Claims Including Third Parties Number LossContingencyPendingClaimsIncludingThirdPartiesNumber	920	case
CY2021Q4	amrx	Loss Contingency Number Of Cases LossContingencyNumberOfCases	120	case
CY2021Q4	amrx	Loss Contingency Number Of States With Cases LossContingencyNumberOfStatesWithCases	11	state
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	53000000	USD
CY2020	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	3000000	USD
CY2019	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	100000	USD
CY2020Q4	amrx	Dueto Related Parties Tax Distribution DuetoRelatedPartiesTaxDistribution	0	USD
CY2021Q4	amrx	Dueto Related Parties Tax Distribution DuetoRelatedPartiesTaxDistribution	0	USD
CY2020Q3	amrx	Payments To Acquire Additional Interest In Subsidiaries Including Distribute Earnings PaymentsToAcquireAdditionalInterestInSubsidiariesIncludingDistributeEarnings	3000000	USD
CY2020Q3	amrx	Noncontrolling Interest Number Of Subsidiaries Acquired NoncontrollingInterestNumberOfSubsidiariesAcquired	1	subsidiary
CY2020Q3	amrx	Payments To Acquire Additional Interest In Subsidiaries Distribute Earnings PaymentsToAcquireAdditionalInterestInSubsidiariesDistributeEarnings	1000000	USD
CY2020Q3	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	2000000	USD
CY2021Q4	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-41203000	USD
CY2020	amrx	Changes In Reallocation Of Ownership Interests ChangesInReallocationOfOwnershipInterests	-47000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	16717000	USD
CY2021	amrx	Changes In Reallocation Of Ownership Interests ChangesInReallocationOfOwnershipInterests	-226000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5814581	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.73
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4559820	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.29
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	210806	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.64
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3986469	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	15.07
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6177126	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.87
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8000000.0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	116681	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.75
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2249216	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.09
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3811229	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.80
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5600000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	342350	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.76
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	417379	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.09
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3051500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.17
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5300000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1930911	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.99
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3000000.0	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	7000000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1100000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3600000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.75
CY2021	amrx	Allocated Share Based Compensation Incremental Expense AllocatedShareBasedCompensationIncrementalExpense	900000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	51000000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M12D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28412000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20750000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21679000	USD
CY2021	amrx	Business Combination Deferred Consideration Liability Fair Value Gross BusinessCombinationDeferredConsiderationLiabilityFairValueGross	30500000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5900000	USD
CY2020Q3	amrx	Payments To Acquire Additional Interest In Subsidiaries Including Distribute Earnings PaymentsToAcquireAdditionalInterestInSubsidiariesIncludingDistributeEarnings	3000000	USD
CY2020Q3	amrx	Noncontrolling Interest Number Of Subsidiaries Acquired NoncontrollingInterestNumberOfSubsidiariesAcquired	1	subsidiary
CY2020Q3	amrx	Payments To Acquire Additional Interest In Subsidiaries Distribute Earnings PaymentsToAcquireAdditionalInterestInSubsidiariesDistributeEarnings	1000000	USD
CY2020Q3	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	2000000	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	9000000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	8000000	USD
CY2019Q1	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	0	USD
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2021	amrx	Number Of Product Families NumberOfProductFamilies	250	product
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2093669000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1302004000	USD
CY2021	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	22692000	USD
CY2021	us-gaap	Gross Profit GrossProfit	768973000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	365504000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	201847000	USD
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	710000	USD
CY2021	us-gaap	Royalty Expense RoyaltyExpense	7716000	USD
CY2021	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	8055000	USD
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-25000000	USD
CY2021	us-gaap	Restructuring Charges RestructuringCharges	1857000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	200000	USD
CY2021	us-gaap	Unusual Or Infrequent Item Net Gain Loss UnusualOrInfrequentItemNetGainLoss	5368000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	152716000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1992523000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1329551000	USD
CY2020	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	34579000	USD
CY2020	us-gaap	Gross Profit GrossProfit	628393000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	326727000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	179930000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2680000	USD
CY2020	us-gaap	Royalty Expense RoyaltyExpense	10655000	USD
CY2020	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	8988000	USD
CY2020	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-5860000	USD
CY2020	us-gaap	Restructuring Charges RestructuringCharges	2398000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	91155000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1626373000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1147214000	USD
CY2019	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	126162000	USD
CY2019	us-gaap	Gross Profit GrossProfit	352997000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	289598000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	188049000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	46619000	USD
CY2019	us-gaap	Royalty Expense RoyaltyExpense	14238000	USD
CY2019	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	16388000	USD
CY2019	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-12442000	USD
CY2019	us-gaap	Restructuring Charges RestructuringCharges	34345000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-248682000	USD
CY2021	us-gaap	Unusual Or Infrequent Item Loss Gross UnusualOrInfrequentItemLossGross	10000000	USD
CY2021	us-gaap	Insurance Recoveries InsuranceRecoveries	5000000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20614000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22344000	USD
CY2021Q3	amrx	Number Of Facilities Damaged NumberOfFacilitiesDamaged	2	facility
CY2021	us-gaap	Unusual Or Infrequent Item Loss Gross UnusualOrInfrequentItemLossGross	10368000	USD
CY2021	us-gaap	Unusual Or Infrequent Item Insurance Proceeds UnusualOrInfrequentItemInsuranceProceeds	5000000	USD
CY2021	us-gaap	Unusual Or Infrequent Item Net Of Insurance Proceeds UnusualOrInfrequentItemNetOfInsuranceProceeds	5368000	USD

Files In Submission

Name	View Source	Status
0001723128-22-000006-index-headers.html	Edgar Link	pending
0001723128-22-000006-index.html	Edgar Link	pending
0001723128-22-000006.txt	Edgar Link	pending
0001723128-22-000006-xbrl.zip	Edgar Link	pending
amrx-20211231.htm	Edgar Link	pending
amrx-20211231.xsd	Edgar Link	pending
amrx-2021123110xkexx231.htm	Edgar Link	pending
amrx-2021123110xkexx311.htm	Edgar Link	pending
amrx-2021123110xkexx312.htm	Edgar Link	pending
amrx-2021123110xkexx313.htm	Edgar Link	pending
amrx-2021123110xkexx321.htm	Edgar Link	pending
amrx-2021123110xkexx322.htm	Edgar Link	pending
amrx-2021123110xkexx323.htm	Edgar Link	pending
amrx-20211231_cal.xml	Edgar Link	unprocessable
amrx-20211231_def.xml	Edgar Link	unprocessable
amrx-20211231_g1.jpg	Edgar Link	pending
amrx-20211231_htm.xml	Edgar Link	completed
amrx-20211231_lab.xml	Edgar Link	unprocessable
amrx-20211231_pre.xml	Edgar Link	unprocessable
amrx2021311210-kexx211.htm	Edgar Link	pending
amrx2021311210-kexx25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMRX
Amneal Pharmaceuticals, Inc. Stock $amrx

2021 Q4 Form 10-K Financial Statement

#000172312822000006 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRX Amneal Pharmaceuticals, Inc. Stock $amrx

2021 Q4 Form 10-K Financial Statement

#000172312822000006 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRX
Amneal Pharmaceuticals, Inc. Stock $amrx